AMPH (72) RAPP (30) SNDX (17) SLN (44) ⌘ Pro Terminal →

Verastem Inc. (VSTM) — RQD Stock Rating Cockpit

$9.75 +0.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.75

Verastem Inc. (VSTM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VSTM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.75 (+0.93% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VSTM ranks #562 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VSTM compare to AMPH and RAPP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VSTM?

▼

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.75 (-0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY VSTM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (44% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 61.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.45+25.4% Next Q

Q2 (-2Q)

Grade E$9.34+8.1% Next Q

Q3 (-1Q)

Grade E$10.10-3.5% Next Q

Current

Grade D-$9.75-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VSTM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.27) and Max Pain ($10.24) forces dealer call-delta covering toward $11.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

61.230 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE86% OF RANGE

L: $3$9.75H: $11

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on VSTM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and -11.72% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

19/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like VSTM

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

✓Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +63.87%▲ ASCENDING CHANNEL

2026-11-03O $9.66H $9.75L $9.66C $9.75VOL 2.41M

RES: $10.39SUP: $7.01SMA50: $8.27SMA200: $6.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VSTM Butterfly Map → + Track VSTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #562 of 1016 ⚔️ AMPH vs VSTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VSTM vs. AMPH, RAPP, SNDX, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #562 by composite RQD confidence (36/100, grade D-) and #335 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with VSTM at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VSTM ACTIVE Verastem Inc.	D-	36/100	—	—	-35.0%	+0.93%	$1.18B	Benchmark Subject
AMPH Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	+2.93%	$1.18B	/amph-vs-vstm →
RAPP Rapport Therapeutics Inc.	E	30/100	—	—	-22.9%	+3.47%	$1.20B	/rapp-vs-vstm →
SNDX Syndax Pharmaceuticals Inc.	E	17/100	—	—	-35.0%	-3.53%	$1.22B	/sndx-vs-vstm →
SLN Silence Therapeutics Plc American Depository Share	D	44/100	—	61.5%	-35.0%	-0.25%	$1.23B	/sln-vs-vstm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001526119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M , and -88.0% cumulative change since FY2023) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.9M	-$209.5M	-$137.5M	-$137.5M	$246.4M	—
FY2024 (FY)	2024-12-31	$10.0M	-$130.6M	-$104.8M	-$104.8M	$101.5M	—
FY2023 (FY)	2023-12-31	$257.8M	-$87.4M	-$86.5M	-$86.5M	—	—

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VSTM compare to AMPH and RAPP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.75 (+0.93% on volume of 2,411,837 shares), positioning the stock +17.90% above its 50-day simple moving average ($8.27) and +57.26% above its 200-day simple moving average ($6.20). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 85.5% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.53 to $10.97).

VSTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VSTM stock right now?

Verastem Inc. (VSTM) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is VSTM's 12-month price target and RQD AI Jury consensus?

VSTM's 12-month base price target is $8.78 (range $6.85 to $11.36), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VSTM — Verastem Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VSTM scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (4 / 20): Per the RQD rating, ROIC is -35% and FCF yield is -11.72%. This is the weakest pillar and indicates the business is currently consuming cash rather than generating it. For a prospective investor, the upside case depends on future revenue scaling faster than current losses, which the source data does not demonstrate.
Whale 13F Flow (16 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar, suggesting institutional interest, though the source data does not include the underlying holder detail to confirm the pattern.
Insider Conviction (3 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low. This is a weak signal of insider confidence and a valuation consideration an investor should weigh.
Macro Regime Fit (8 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. The stock is assessed as moving in line with the broader market, offering neither a defensive profile nor a clear macro tailwind in the source data.
Forensic Balance Sheet (5 / 20): Per the RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings signal balance sheet vulnerability, a central risk for any prospective investor.

Taken together, the rating suggests the primary upside driver is institutional interest and the primary risk is cash burn and balance sheet strength. The valuation tradeoff is that the share price has moved sharply within its 52-week range, while the underlying cash metrics remain negative.

Business

Verastem Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is publicly traded with a market capitalization of $1.2B. The source data does not describe specific products, customers, or revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$30.9M	$-170.1M	$-209.5M	N/A	$-137.5M	$205.0M	N/A
FY 2024	$10.0M	$-115.0M	$-130.6M	N/A	$-104.8M	$88.8M	N/A
FY 2023	$0.0M	$-92.1M	$-87.4M	N/A	$-86.5M	N/A	N/A

Per the SEC financials, revenue grew from $0.0M in FY 2023 to $30.9M in FY 2025 while losses widened in each period, with FY 2025 net income at $-209.5M. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both indicating financial stress. Debt/Equity is 0.5 per the RQD rating; reported FY debt is not available in source data. Cash was $205.0M at the latest reported period.

Recent Catalysts & News Wire Analysis

Pricing of a $250 Million offering of common stock and pre-funded warrants (Business Wire) is flagged as a YELLOW market wire item; it represents a capital raise.
Mizuho raised its price target on strong trial data (Investing.com) is flagged GREEN as a CATALYST.
Zacks analysis referencing a potential 79% rally per Wall Street analyst expectations (Zacks Investment Research) is flagged GREEN as a CATALYST.
Additional YELLOW market wire items from Yahoo! Finance Canada, Yahoo Finance UK, and Moomoo cover market action and institutional positioning without specific detail in the source data.
Per the Butterfly Supply-Chain Graph, supply chain is NONE and there are no butterfly links or proprietary signals.

Analyst View & Smart Money Ownership

Per the analyst data and holders sections, no analyst consensus, price targets (other than the Mizuho reference in news), insider Form 4 filings, 13F holder detail, or Congressional trades are provided in the source data. The Roarable RQD rating's whale flow and insider pillars are the only ownership-related signals available.

Open Questions

What are the company's specific products, approved indications, and revenue sources behind the $30.9M FY 2025 revenue figure?
What is the cash runway given $205.0M in cash against FY 2025 free cash flow of $-137.5M, and how does the $250 Million offering change that picture?
What are the underlying 13F holder names and Form 4 insider transactions behind the whale and insider pillar scores?
What trial results drove the Mizuho price target increase, and what is the trial's regulatory status?
What debt obligations exist, since reported debt is not available in source data?

VSTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Verastem Inc. (VSTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VSTM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

Verastem, Inc. (VSTM) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 22h ago

Verastem, Inc. (VSTM) stock price, news, quote and history

Yahoo Finance UK report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Mizuho raises Verastem stock price target on strong trial data

Investing.com report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Business Wire report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Zacks Investment Research • 1d ago

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

Zacks Investment Research report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Verastem (VSTM) Stock Forum and Discussion

Moomoo report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM)

Seeking Alpha report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Verastem Oncology (VSTM) Shares Surge 20% Premarket on CEO Change and $250M Stock Offering

GuruFocus report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VSTM Bull vs. Bear Conversation Board — What's Your Call at $9.75?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VSTM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $8.50 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VSTM (D- • RQD 36/100) a Buy at $9.66?

Welcome to the VSTM (Verastem Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.53 (-22.0%)

Spot @ $9.66

Pump the brakes on VSTM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VSTM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Verastem Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.08 (+25.1%)

Spot @ $9.66

VSTM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VSTM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $9.66 (52-wk range $3.43 - $10.82), any beat on forward guidance forces shorts and underweight funds to chase.